Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (July 2020)
31 slides from Pds Biotechnology's investor presentation, Jul 31, 2020
Slide 1: A new generation of multi-functional cancer immunotherapies
©) PDs Biotechnology Anew generation of multi-functional cancer immunotherapies Frank Bedu-AddoPh.D. President & CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activi
Slide 3: PDS Biotechnology leadership team has demonstrated success in development and commercialization
PDS Biotechnology leadership team has demonstrated success in the development and commercialization of leading pharmaceutical products ™ Frank Bedu-Addo, PhD Senior executive experience with management of strategy and Chief Executive Officer execution at both large pharma and biotechs Re gees 72) Sc
Slide 4: PDS Biotech is well-poised to transform vaccines and cancer treatment
PDS Biotech is well-poised to transform vaccines and cancer treatment by delivering promising immunotherapies Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways 2 Demonstrated potential for strong clinical efficacy and durability of response with m al to
Slide 5: PDS Biotech is a clinical stage biotechnology company developing immunotherapies on Versamune platform
PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on the proprietary Versamune® platform CORPORATE OVERVIEW VERSAMUNE® PLATFORM PIPELINE = Publicly listed on NASDAQ: = Versatile and potent T-cell- Oncology PDSB activating platform = PDS0101 (Phase 2
Slide 6: Versamune Platform
Slide 7: Versamune: proprietary T-cell activating platform
Versamune®: proprietary T-cell activating platform Engineered to induce robust, targeted anti-tumor responses in vivo Versamune® is based on proprietary, positively charged and immune activating lipids that form spherical nanoparticles in aqueous media The nanoparticles are sized to mimic viruses, w
Slide 8: Versamune has demonstrated potential to overcome well-established challenges of immunotherapy
Versamune® has demonstrated potential to overcome well-established challenges of immunotherapy in oncology and infectious disease Challenges of Immunotherapy How Versamune® May Overcome the Challenges Inability to perform the necessary steps to induce a strong therapeutic killer T-cell response in-v
Slide 9: Greater quantity and quality of Versamune-induced killer T-cells
Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies 500 1750 on Oa 450 Re 1500 : E§ 400 ? ¢ Untreat
Slide 10: Combination of Versamune and a proprietary antigen
Combination of Versamune® and a proprietary antigen Engineered for simplicity and ease of administration Vials of HPV16 mix (L) Versamune® formulation Delivered via and Versamune® (R) is mixed before injection* subcutaneous injection PDS Biotechnology
Slide 11: fe "5
fe "5
Slide 12: Clinical strategy in advanced cancer
Clinical strategy in advanced cancer: Focus on efficiency and risk mitigation to proof of concept Versamune®-based immunotherapies are being developed as combination therapies to exploit the demonstrated synergies between Versamune® and other anti-cancer agents * Checkpoint inhibitors have shown con
Slide 13: Versamune-based immunotherapy + checkpoint inhibitors: strong synergy
Versamune®-based immunotherapy + checkpoint inhibitors: Strong synergy leads to enhanced anti-tumor efficacy Preclinical studies: Checkpoint inhibitor ineffective in treating B16 melanoma, a notoriously difficult model PDS0104 promotes infiltration of active killer T-cells into tumors + Checkpoint i
Slide 14: PDS Biotech's immuno-oncology pipeline combines Versamune with proprietary tumor antigens
PDS Biotech’s immuno-oncology pipeline combines the Versamune® platform with proprietary tumor antigens across several cancer types PRODUCT INDICATION COMBINATION Oncology First line treatment of recurrent / metastatic head and neck cancer PDSo101 (HPV16) PDSo101 (HPV36) Advanced HPV-associated mali
Slide 15: PDS0101 designed to treat cancers caused by human papillomavirus (HPV)
PDS0101 designed to treat cancers caused by human papillomavirus (HPV) Approximately 43,000 patients are diagnosed with caners where HPV is often found each year in US; approximately 35,000 cases are caused directly by HPV + Oropharyngeal (head & neck) cancers Females (24,391) Males (18,280) — >18,0
Slide 16: PDS0101 Phase 1 clinical trial: high levels of HPV-specific killer T-cells
PDS0101 Phase 1 clinical trial: Unique in vivo demonstration of high levels of HPV-specific killer T-cells in circulating blood Clinical study results successfully demonstrate translation of Versamune®’s multi- functional mechanism of action between pre-clinical models and humans um Activated Killer
Slide 17: Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses
Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses at all three tested doses A post-hoc, retrospective analysis, demonstrated complete lesion regression in at least 60% of evaluable patients (6/10) as early as 1-3 months after treatment — No lesion recurrence oc
Slide 18: Planned Phase 2 study of PDS0101 with KEYTRUDA in head and neck cancer
Planned Phase 2 study of PDS0101 in combination with KEYTRUDA® in first-line treatment of recurrent/metastatic head and neck cancer (HNC) » PDS Biotechnology-sponsored Phase 2 study with KEYTRUDA® supplied by Merck — Keytruda®: first immunotherapy approved as SOC for first line treatment of recurren
Slide 19: Investigator-Led Phase 2 studies of PDS0101 in combination therapy
Investigator-Led Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety in treatment of advanced HPV cancers Phase 2 Open Label Study A é Funded By (Safety and Efficacy) Important Considerations + Advanced HPV-associated malignancies —all types + NCI selection and confir
Slide 20: Infectious Disease
Slide 21: PDS Biotech's infectious disease pipeline combines Versamune with proprietary antigens
PDS Biotech’s infectious disease pipeline combines the Versamune® platform with proprietary antigens across several diseases PRODUCT INDICATION COMBINATION jc |r [res |R PARTNER(S) PDSo201 ' f @Farma rene 7 Prevention of tuberculosis D Ke PDSo202 A » [National nstitvte of ener Universal prevention o
Slide 22: PDS0202: Versamune enhances neutralizing antibody levels against influenza strains
PDS0202: Versamune® dramatically enhances neutralizing antibody levels against various influenza strains and enables significant dose sparing The addition of Versamune® to Fluzone®, a seasonal influenza vaccine, resulted in a 40-fold increase in protective HAI titers— achieving superior levels of HA
Slide 23: Versamune-based vaccines induce strong antibody, helper and killer T-cell responses
IgG1 Titer ( 1/ 1C50) Versamune®-based vaccines induce strong antibody, helper and killer T-cell responses against an antigen to provide superior protection Versamune® induces both potent antibody mediated responses and high levels of helper and killer T-cells vs. CFA when both are administered with
Slide 24: Preclinical testing of Versamune-based COVID-19 vaccine candidates ongoing
Preclinical testing of Versamune®-based COVID-19 vaccine candidates ongoing with a clear target profile Induction of highly-potent, SARS-CoV-2-specific killer T-cells 2 Demonstrate high levels of both SARS-CoV-2-specific T-cell and antibody response after a single dose 3 No safety signals 4 Poised f
Slide 25: PDS0203: COVID-19 vaccine induces rapid and potent antibody responses
PDS0203: Versamune®-based COVID-19 vaccine induces rapid and potent antibody responses to SARS-CoV-2 in two weeks Initial preclinical data suggest Versamune® induces antibodies at a level equivalent to those observed in hospitalized COVID-19 patients within 2 weeks of vaccination Day 14: Neutralizin
Slide 26: PDS0203: COVID vaccine induces strong T-cell responses against SARS-CoV-2
PDS0203: Versamune®-based COVID vaccine uniquely induces strong T- cell responses against SARS-CoV-2 in two weeks Preclinical data suggest Versamune® induces T-cells — including polyfunctional CD4+ (helper) & CD8+ (killer) T-cells - against SARS-CoV-2 when combined with either the Spike S1 protein o
Slide 27: Intellectual Property and Financials
Slide 28: Multiple layers of technology and product protection through mid-2030s
Multiple layers of technology and product protection for Versamune®-related products through mid-2030s » Versamune® and associated patents are owned and licensed by PDS Biotech * Patents cover methods and compositions stimulating/promoting an immune response with Versamune® technology in various for
Slide 29: Strong financial position to support near-term milestones
Strong financial position to support near-term milestones Timing of 2020 milestones will be impacted by the COVID-19 pandemic Cash” $21.0M Share Price® $3.89 Market Cap* $59.9M Debt" = Y Ppso101 (HPV): Initiation of PDS Biotech-NCl Phase 2 combination study in advanced HPV- associated cancers PDS010
Slide 30: PDS Biotech poised to transform vaccines and cancer treatment
PDS Biotech poised to transform vaccines and cancer treatment by fulfilling the promise of immunotherapy Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways 2 Demonstrated potential for strong clinical efficacy and durability of response with minimal toxi
Slide 31: PDS Biotechnology
”) PDS Biotechnology Anew generation of multi-functional cancer immunotherapies
PDS Biotechnology — Investor Presentation (July 2020) on 6ix